Orchard Therapeutics plc (ORTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ORTX Stock Price Chart Interactive Chart >
ORTX Price/Volume Stats
| Current price | $4.91 | 52-week high | $8.13 |
| Prev. close | $5.12 | 52-week low | $3.60 |
| Day low | $4.75 | Volume | 74,800 |
| Day high | $5.11 | Avg. volume | 120,210 |
| 50-day MA | $5.42 | Dividend yield | N/A |
| 200-day MA | $5.18 | Market Cap | 62.20M |
Orchard Therapeutics plc (ORTX) Company Bio
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of gene therapies. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). It operates through the United Kingdom and United States geographical segments. The company was founded in August 2018 and is headquartered in London, the United Kingdom.
Latest ORTX News From Around the Web
Below are the latest news stories about ORCHARD THERAPEUTICS PLC that investors may wish to consider to help them evaluate ORTX as an investment opportunity.
Orchard adds ~32% as FDA clears trial for metabolic disorder drug
|
ORTX Price Returns
| 1-mo | -10.48% |
| 3-mo | 29.62% |
| 6-mo | 1.22% |
| 1-year | -36.80% |
| 3-year | -92.66% |
| 5-year | N/A |
| YTD | 32.35% |
| 2022 | -71.89% |
| 2021 | -69.44% |
| 2020 | -68.58% |
| 2019 | -12.59% |
| 2018 | N/A |
Loading social stream, please wait...